AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34686616
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (noncaloric juice)
Trial: 33320868
Drug: Positive-control (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive-control (140 ml of water)
Trial: 33320868
Drug: Placebo-trial (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-trial (140 ml NO3‐ depleted beetroot juice)
Trial: 33320868
Drug: Negative-control (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-control (140 ml of water)
Trial: 35388235
Drug: Nebulized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized lidocaine 1.0 mg/kg body weight (BW), q12h for 14 days
Trial: 35388235
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide 1 μg/kg, q12h for 14 days
Trial: 35028769
Drug: VS+PBMT (vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS+PBMT (vaginal stretching combined with photobiomodulation therapy)
Trial: 35028769
Drug: VS+shamPBMT (vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS+shamPBMT (vaginal stretching combined with sham photobiomodulation therapy)
Trial: 33575340
Drug: Hospital-based systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based systemic rehabilitation (50-minute sessions, three times weekly for 12 weeks)
Trial: 32292360
Drug: Drug plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug plus psychotherapy (DPP) - olanzapine and metacognitive training
Trial: 32292360
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (DT) - olanzapine only
Trial: 34510258
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with surgery (22%)
Trial: 34510258
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (80% completed treatment with curative intent)
Trial: 34897226
Drug: Oral Naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Naltrexone (NTX)
Trial: 32330571
Drug: Riboflavin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (1.6 mg/d) for 16 weeks, n=24
Trial: 36249252
Drug: Cansino vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cansino vaccine
Trial: 36249252
Drug: Sinovac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovac vaccine
Trial: 32167792
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2100 mg/day)
Trial: 33392664
Drug: HEMOCIN® patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEMOCIN® patch
Trial: 33392664
Drug: No systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systematic treatment (control)
Trial: 36684501
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 300 mg/day
Trial: 36123783
Drug: EMP16-120/40 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMP16-120/40 (120 mg orlistat/40 mg acarbose)
Trial: 36123783
Drug: EMP16-150/50 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMP16-150/50 (150 mg orlistat/50 mg acarbose)
Trial: 34748059
Drug: Intratumoral (IT)
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral (IT) tracer injection (2 depots of 1 mL indocyanine green-[99mTc]Tc-nanocolloid)
Trial: 34748059
Drug: Intraprostatic (IP)
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic (IP) tracer injection (4 depots of 0.5 mL indocyanine green-[99mTc]Tc-nanocolloid)
Trial: 32367880
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave therapy (ESWT) once a week for 3 weeks
Trial: 32150855
Drug: UVB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB group (half‐body UVB irradiation, twice weekly over 6 months, with 1 standard erythema dose (SED))
Trial: 35973626
Drug: Local prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local prophylactic antibiotic therapy with vancomycin loaded calcium sulfate beads
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), followed by chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 or capecitabine).
Trial: 33862000
Drug: Standard-of-care (chemoradiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy for 6 months).
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (during neoadjuvant chemotherapy).
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (during adjuvant chemotherapy).
Trial: 33862000
Drug: Standard-of-care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care group (during adjuvant chemotherapy).
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (serious adverse events during the whole treatment period).
Trial: 33862000
Drug: Standard-of-care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care group (serious adverse events during the whole treatment period).
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (serious adverse events during adjuvant therapy).
Trial: 33862000
Drug: Standard-of-care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care group (serious adverse events during adjuvant therapy).
Trial: 33862000
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (treatment-related deaths).
Trial: 33862000
Drug: Standard-of-care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care group (treatment-related deaths).
Trial: 34273650
Drug: Black chokeberry
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black chokeberry dried pomace (30 g/kg of feed)
Trial: 34273650
Drug: Black currant
RxNorm normalized name: Black currant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black currant dried pomace (30 g/kg of feed)
Trial: 34273650
Drug: Raspberry dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raspberry dried pomace (30 g/kg of feed)
Trial: 39557730
Drug: Peptide receptor
RxNorm normalized name: Polypeptide receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide receptor radionuclide therapy (PRRT)
Trial: 32078815
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL of 0.9% saline)
Trial: 35661378
Drug: TTP399 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTP399 (800 mg)
Trial: 32580838
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 30-minute intervals with a pulse dose of 5 mL (Group A)
Trial: 32580838
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 60-minute intervals with a pulse dose of 10 mL (Group B)
Trial: 34726317
Drug: Continuous low-energy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low-energy diet (CLED) - 8 weeks/56 days of daily Optifast 820 kcal (3430 kJ) diet
Trial: 34460933
Drug: GOP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GOP infusion (n = 14)
Trial: 32294346
Drug: SEP‐363856 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP‐363856 (50 mg or 75 mg)
Trial: 35349757
Drug: No ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No ganciclovir treatment (Control)
Trial: 35739147
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) monotherapy
Trial: 35739147
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) + subthreshold laser (SL) combination therapy
Trial: 32686217
Drug: Tested preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tested preparation
Trial: 33081817
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with macrolide azithromycin and hydroxychloroquine
Trial: 34322703
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus low-dose cytarabine
Trial: 35255426
Drug: Cyanidin‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanidin‐ and delphinidin‐rich extract (CDRE) providing 320.4 mg of anthocyanins (90% cyanidin and delphinidin)
Trial: 33958495
Drug: Vibroacoustic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibroacoustic therapy using the VITAFON-2 apparatus
Trial: 35737102
Drug: Group iSLN:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group iSLN: bilateral perineural injection with 4 mg dexamethasone around the internal branch of superior laryngeal nerve
Trial: 35737102
Drug: Group Spray:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Spray: 4 mg dexamethasone sprayed on the vocal cord
Trial: 33258032
Drug: Stent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent treatment
Trial: 35219356
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with fluvoxamine
Trial: 35485333
Drug: Rilpivirine plus
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine plus darunavir/cobicistat (25 mg rilpivirine plus 800/150 mg darunavir/cobicistat once daily)
Trial: 35485333
Drug: Standard three-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard three-drug therapy (late switch group)
Trial: 33691730
Drug: Diuretic (furosemide)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic (furosemide)
Trial: 33646835
Drug: Oxford/AstraZeneca vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxford/AstraZeneca vaccine (ChAdOx1 nCoV‐19)
Trial: 36136951
Drug: Bifiform Kids
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bifiform Kids (2 chewable tablets twice per day for 21 days)
Trial: 34116393
Drug: Magnesium treatment
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium treatment for 12 weeks
Trial: 33009185
Drug: Rectus sheath
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectus sheath block (RSB) with 2 mg/kg of levobupivacaine
Trial: 33009185
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with 12.5 mg hyperbaric bupivacaine and 0.5 mg diamorphine
Trial: 36057030
Drug: Rebaudioside A
RxNorm normalized name: Rebaudioside A
DrugBank: Rebaudioside A (DB15136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebaudioside A (3 g)
Trial: 36690404
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) infusion
Trial: 34339618
Drug: Clonidine (CLON)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (CLON) infusion
Trial: 32461053
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin (0.1%)‐metronidazole (1%) gel treatment
Trial: 32633244
Drug: Manosar® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manosar® (2 g of d-mannose + 140 mg of proanthocyanidins)
Trial: 32633244
Drug: Isolated PAC
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated PAC (240 mg of continuous-release proanthocyanidins)
Trial: 35042152
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, every 3 weeks)
Trial: 33217335
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg and 25 mg)
Trial: 34233727
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with TNFi plus MTX
Trial: 34233727
Drug: Switched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched therapy with tacrolimus (TAC) plus MTX
Trial: 34233727
Drug: Switched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched therapy with TAC plus MTX
Trial: 34849920
Drug: Standard in
RxNorm normalized name: Standard infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard in vitro fertilization (IVF) with flexible GnRH antagonist protocol and hCG as ovulatory trigger
Trial: 33655380
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab 2 mg/kg at Weeks 0, 4, then every 8 weeks through Week 52
Trial: 35241023
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic acid (TXA)
Trial: 32521015
Drug: diacerein 50
RxNorm normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein 50 mg once daily for 1 month and twice daily thereafter (n=140)
Trial: 32521015
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg once daily (n=148)
Trial: 32640842
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (Humalog®)
Trial: 32978185
Drug: Critical care
RxNorm normalized name: Adult critical care formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critical care telehealth program (daily telemedical rounds at ICU)
Trial: 34590519
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Trial: 34118635
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication (long-term use)
Trial: 34118635
Drug: Antidepressants plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants plus lithium (long-term use)
Trial: 34118635
Drug: Antipsychotics (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics (long-term use)
Trial: 34118635
Drug: Brief psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychological therapy (ASSIP) added to medication
Trial: 32027542
Drug: Heated-water exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated-water exercise therapy (HWET) for 12 weeks
Trial: 32027542
Drug: Land-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based exercise therapy (LBET) for 12 weeks
Trial: 32027542
Drug: Heated-water exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated-water exercise therapy (HWET)
Trial: 32027542
Drug: Land-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based exercise therapy (LBET)
Trial: 33862001
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg tablets twice per day for up to 2 years)
Trial: 35502234
Drug: Liposomal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal drugs for cancer therapy
Trial: 32033103
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg/kg/b.m.
Trial: 32033103
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg/kg/b.m.
Trial: 32033103
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 and 6 mg/kg/b.m.)
Trial: 34795281
Drug: PPQ level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPQ level of 15.4 ng/mL
Trial: 35545388
Drug: Development and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development and Well‐Being Assessment SDA tool as an adjunct to usual clinical care
Trial: 34260693
Drug: Endoscopic eradication
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic eradication therapy (EET)
Trial: 34645661
Drug: Specialised outpatient
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised outpatient treatment in CAG Bipolar
Trial: 34645661
Drug: Generalised community‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generalised community‐based outpatient treatment
Trial: 33208330
Drug: Semantic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic treatment for lexical retrieval deficits in the optimal language determined by the BiLex model.
Trial: 33208330
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving treatment in the language opposite to the model's recommendation.
Trial: 34182611
Drug: AZD8154 inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8154 inhaled doses (0.1–7.7 mg)
Trial: 34182611
Drug: AZD8154 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8154 IV infusion (0.15 mg)
Trial: 34182611
Drug: AZD8154 inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8154 inhaled doses (0.6, 1.8, and 3.1 mg) with once-daily dosing on Days 4–12
Trial: 34182611
Drug: AZD8154 inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8154 inhaled route
Trial: 37470445
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug (control)
Trial: 34001174
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (1 to 2 units of 200 to 250 ml) along with local standard treatment
Trial: 37018790
Drug: Local standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local standard treatment alone
Trial: 33905041
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (0.25 g)
Trial: 33905041
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (20.0 g) with vitamin C (0.25 g)
Trial: 33905041
Drug: Placebo (20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20.0 g of white rice flour) with vitamin C (0.25 g)
Trial: 32728763
Drug: Breast augmentation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast augmentation with various implant volumes and textures
Trial: 35906581
Drug: Family-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive behavioural therapy (CBT)
Trial: 35906581
Drug: Family-based relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based relaxation therapy
Trial: 32665656
Drug: Epinephrine group
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine group (5 mcg ml-1, n=41)
Trial: 32570252
Drug: Tofacitinib (JAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (JAK inhibitor)
Trial: 32570252
Drug: Filgotinib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib and upadacitinib (JAK inhibitors)
Trial: 32570252
Drug: Vedolizumab (α4β7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (α4β7 integrin inhibitor)